Pharmacogenetics of opioids

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 3, 2007, Pages 429-444

  Somogyi, Andrew A ^a   Barratt, Daniel T ^a   Coller, Janet K ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ASIMADOLINE; BREMAZOCINE; CODEINE; CYTOCHROME P450 2D6; DEXTROPROPOXYPHENE; DIAMORPHINE; DIHYDROCODEINE; DIHYDROMORPHINE; DRUG CARRIER; DRUG METABOLIZING ENZYME; FENTANYL; HYDROCODONE; HYDROMORPHONE; LEVOMETHADONE; LOPERAMIDE; METHADONE; MORPHINE; MORPHINE 6 GLUCURONIDE; MU OPIATE RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1; NALOXONE; NALTREXONE; OPIATE; OXYCODONE; OXYMORPHONE; PENTAZOCINE; PETHIDINE; QUINIDINE; TRAMADOL; UNINDEXED DRUG;

ALCOHOLISM; ANTINOCICEPTION; ANXIETY; CANCER PAIN; CLINICAL TRIAL; DEMETHYLATION; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; DRUG SUBSTITUTION; DRUG TOLERANCE; GENETIC IMMUNIZATION; GENOTYPE; HEADACHE; HUMAN; LOADING DRUG DOSE; NAUSEA; NOCICEPTION; NONHUMAN; OPIATE ADDICTION; PAIN; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOGENOMICS; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PRURITUS; REVIEW; SEDATION; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; VOMITING; XEROSTOMIA;

ANALGESICS, OPIOID; ANIMALS; HUMANS; PAIN; PAIN MEASUREMENT; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, OPIOID;

EID: 33847648461     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100095     Document Type: Review

References (191)

1. Macintyre, P.E. & Ready, L.B. Acute Pain Management: A Practical Guide 2nd edn. (WB Saunders, London, 2001).
2. Aubrun, F. et al. Relationships between measurement of pain using visual analog score and morphine requirements during postoperative intravenous morphine titration. Anesthesiology 98, 1415-1421 (2003).
3. Ashby, M., Fleming, B., Wood, M. & Somogyi, A. Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. J. Pain Symptom Manage 14, 157-167 (1997).
4. Samer, C.F., Desmeules, J.A. & Dayer, P. Individualizing analgesic prescription Part I: pharmacogenetics of opioid analgesics. Personalized Med. 3, 239-269 (2006).
5. Fillingim, R.B. Social and environmental influences on pain: implications for pain genetics In The Genetics of Pain (Progress in Pain Research and Management) (ed. Mogil, J.S.) 283-303 (IASP Press, Seattle, 2004).
6. Mogil, J.S. et al. Heritability of nociception II. "Types" of nociception revealed by genetic correlation analysis. Pain 80, 83-93 (1999).
7. Xu, X.-J. & Wiesenfeld-Hallin, Z. Individual differences in pain: rat models In The Genetics of Pain (Progress in Pain Research and Management) (ed. Mogil, J.S.) 107-121 (IASP Press, Seattle, 2004).
8. Belfer, I. et al. Candidate gene studies of human pain mechanisms: methods for optimizing choice of polymorphisms and sample size. Anesthesiology 100, 1562-1572 (2004).
9. Tegeder, I. et al. GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat. Med. 12, 1269-1277 (2006).
10. Kim, H. et al. Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain 109, 488-496 (2004).
11. Mogil, J.S. et al. Melanocortin-1 receptor gene variants affect pain and μ-opioid analgesia in mice and humans. J. Med. Genet. 42, 583-587 (2005).
12. Zubieta, J.-K. et al. COMT val158met genotype affects μ-opioid neurotransmitter responses to a pain stressor. Science 299, 1240-1243 (2003).
13. Diatchenko, L. et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum. Mol. Genet. 14, 135-143 (2005).
14. Diatchenko, L. et al. Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain 125, 216-224 (2006).
15. Ikeda, K. et al. How individual sensitivity to opiates can be predicted by gene analyses. Trends Pharmacol. Sci. 26, 311-317 (2005).
16. Lötsch, J. & Geisslinger, G. Are μ-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol. Med. 11, 82-89 (2005).
17. Bond, C. et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters b-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl. Acad. Sci. USA 95, 9608-9613 (1998).
18. Befort, K. et al. A single nucleotide polymorphic mutation in the human μ-opioid receptor severely impairs receptor signaling. J. Biol. Chem. 276, 3130-3137 (2001).
19. Beyer, A. et al. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J. Neurochem. 89, 553-560 (2004).
20. Zhang, Y. et al. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J. Biol. Chem. 280, 32618-32624 (2005).
21. Mayer, P. & Hollt, V. Pharmacogenetics of opioid receptors and addiction. Pharmacogenet. Genom. 16, 1-7 (2006).
22. Lötsch, J. et al. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 12, 3-9 (2002).
23. Skarke, C. et al. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin. Pharmacol. Ther. 73, 107-121 (2003).
24. Romberg, R. et al. Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers. Anesthesiology 100, 120-133 (2004).
25. Romberg, R.R. et al. Polymorphism of μ-opioid receptor gene (OPRM1:c.118A > G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology 102, 522-530 (2005).
26. Oertel, B.G. et al. The mu-opioid receptor gene polymorphism 118A > G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet. Genom. 16, 625-636 (2006).
27. Lötsch, J. et al. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin. Pharmacol. Ther. 79, 72-89 (2006).
28. Caraco, Y., Maroz, Y. & Davidson, E. Variability in alfentanil analgesia may be attributed to polymorphism in the mu-opioid receptor. Clin. Pharmacol. Ther. 39, 63 (2001).
29. Klepstad, P. et al. The 118 A > G polymorphism in the human μ-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol. Scand. 48, 1232-1239 (2004).
30. Coulbault, L. et al. Environmental and genetic factors associated with morphine response in the postoperative period. Clin. Pharmacol. Ther. 79, 316-324 (2006).
31. Hirota, T. et al. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug. Metab. Dispos. 31, 677-680 (2003).
32. Lötsch, J. et al. Does the A118G polymorphism at the μ-opioid receptor gene protect against morphine-6-glucuronide toxicity? Anesthesiology 97, 814-819 (2002).
33. Wand, G.S. et al. The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 26, 106-114 (2002).
34. Oslin, D.W. et al. A functional polymorphism of the μ-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28, 1546-1552 (2003).
35. Rakvag, T.T. et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 116, 73-78 (2005).
36. Ross, J.R., Riley, J. & Welsh, K. Genetic variation in the catechol-O-methyl-transferase gene is associated with response to morphine in cancer patients. 11th World Congress on Pain (eds. Flor, H., Kalso, E. & Dostrovsky, J.O.) 461-467 (IASP Press, Seattle, 2006).
37. Mogil, J.S. et al. The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc. Natl. Acad. Sci. USA 100, 4867-4872 (2003).
38. Ross, J.R. et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J. 5, 324-336 (2005).
39. Mikus, G. & Weiss, J. Influence of CYP2D6 genetics on opioid kinetics, metabolism and response. Curr. Pharmacogenom. 3, 43-52 (2005).
40. Sim, S., Ingelman-Sundberg, M., Daly, A.K. & Nebert, D.W. Home page of the Human Cytochrome P450 (CYP) Allele Nomenclature, http://www.cypalleles. ki.se/ (2006).
41. Zanger, U.M., Raimundo, S. & Eichelbaum, M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg's Arch. Pharmacol. 369, 23-37 (2004).
42. Lovlie, R. et al. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics 11, 45-55 (2001).
43. Lang, T. et al. Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J. Pharmacol. Exp. Ther. 311, 34-43 (2004).
44. Guan, S. et al. Intra- and inter-ethnic differences in the allele frequencies of cytochrome P450 2B6 gene in Chinese. Pharm. Res. 23, 1983-1990 (2006).
45. Saito, K. et al. Haplotype analysis of UDP-glucuronosyltransferase 2B7 gene (UGT2B7) polymorphisms in healthy Japanese subjects. Clin. Biochem. 39, 303-308 (2006).
46. Coffman, B.L., King, C.D., Rios, G.R. & Tephly, T.R. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug. Metab. Dispos. 26, 73-77 (1998).
47. Bhasker, C.R. et al. Genetic polymorphism of UDP- glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 10, 679-685 (2000).
48. Dayer, P., Desmeules, J., Leemann, T. & Striberni, R. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 db1/bufI). Biochem. Biophys. Res. Commun. 152, 411-416 (1988).
49. Mortimer, Ö. et al. Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IId1. Clin. Pharmacol. Ther. 47, 27-35 (1990).
50. Kirkwood, L.C., Nation, R.L. & Somogyi, A.A. Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine. Br. J. Clin. Pharmacol. 44, 549-555 (1997).
51. Rasmussen, I. Identification of Cytochrome P450 Isoforms Involved in the Metabolism of Oxycodone Master of Science Thesis, University of Adelaide, Adelaide. pp 141 (2000).
52. Lalovic, B. et al. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab. Dispos. 32, 447-454 (2004).
53. Hutchinson, M.R. et al. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br. J. Clin. Pharmacol. 57, 287-297 (2003).
54. Subrahmanyam, V. et al. Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab. Dispos. 29, 1146-1155 (2001).
55. Paar, W.D., Frankus, P. & Dengler, H.J. The metabolism of tramadol by human liver microsomes. Clin. Invest. 70, 708-710 (1992).
56. Wang, J.-S. & DeVane, C.L. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab. Dispos. 31, 742-747 (2003).
57. Kharasch, E.D., Hoffer, C., Whittington, D. & Sheffels, P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition and miotic effects of methadone. Clin. Pharmacol. Ther. 76, 250-269 (2004).
58. Gerber, J.G., Rhodes, R.J. & Gal, J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 16, 36-44 (2004).
59. Iribarne, C. et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem. Res. Toxicol. 9, 365-373 (1996).
60. Foster, D.J.R., Somogyi, A.A. & Bochner, F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br. J. Clin. Pharmacol. 47, 403-412 (1999).
61. Hutchinson, M.R. & Somogyi, A.A. Relationship between 4,5-epoxymorphinan structure and in vitro modulation of cell proliferation. Eur. J. Pharmacol. 494, 251-262 (2004).
62. Coffman, B.L., Rios, G.R., King, C.D. & Tephly, T.R. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab. Dispos. 25, 1-4 (1997).
63. Kirkwood, L.C., Nation, R.L. & Somogyi, A.A. Glucuronidation of dihydrocodeine by human liver microsomes and the effect of inhibitors. Clin. Exp. Pharmacol. Physiol. 25, 266-270 (1998).
64. Yamada, H. et al. Formation of highly analgesic morphine-6-glucuronide following physiologic concentration of morphine in human brain. J. Toxicol. Sci. 28, 395-401 (2003).
65. Court, M.H. et al. Evaluation of 3′-azido-3′- deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab. Dispos. 31, 1125-1133 (2003).
66. Coffman, B.L. et al. Opioids bind to the amino acids 84 and 118 of UDP-glucuronosyltransferase UGT2B7. Mol. Pharmacol. 63, 283-288 (2003).
67. Findlay, J.W.A., Jones, E.C., Butz, R.F. & Welch, R.M. Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesia. Clin. Pharmacol. Ther. 24, 60-68 (1978).
68. Rogers, J.F. et al. Codeine disposition in smokers and nonsmokers. Clin. Pharmacol. Ther. 32, 218-227 (1982).
69. Findlay, J.W.A. et al. Comparative disposition of codeine and pholcodine in man after single oral doses. Br. J. Clin. Pharmacol. 22, 61-71 (1986).
70. Quiding, H. et al. Plasma concentrations of codeine and its metabolite, morphine, after single and repeated oral administration. Eur. J. Clin. Pharmacol. 30, 673-677 (1986).
71. Shah, J.C. & Mason, W.D. Plasma codeine and morphine concentrations after a single oral dose of codeine phosphate. J. Clin. Pharmacol. 30, 764-766 (1990).
72. Sindrup, S.H. et al. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin. Pharmacol. Ther. 48, 686-693 (1991).
73. Yue, Q.Y. et al. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br. J. Clin. Pharmacol. 28, 639-645 (1989).
74. Chen, Z.R., Somogyi, A.A. & Bochner, F. Polymorphic O-demethylation of codeine. Lancet 2, 914-915 (1988).
75. Chen, Z.R., Somogyi, A.A., Reynolds, G. & Bochner, F. Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. Br. J. Clin. Pharmacol. 31, 381-390 (1991).
76. Yue, Q.Y., Alm, C., Svensson, J.O. & Säwe, J. Quantification of the O- and N-demethylated and the glucuronidated metabolites of codeine relative to the debrisoquine metabolic ratio in urine in ultrarapid, rapid, and poor debrisoquine hydroxylators. Ther. Drug Monit. 19, 539-542 (1997).
77. Williams, D.G., Patel, A. & Howard, R.F. Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. Br. J. Anaesth. 89, 839-845 (2002).
78. Hedenmalm, K. et al. Urinary excretion of codeine, ethylmorphine, and their metabolites: relation to the CYP2D6 activity. Ther. Drug Monit. 19, 643-649 (1997).
79. Yue, Q.Y. & Säwe, J. Interindividual and interethnic differences in codeine metabolism In Pharmacogenetics of Drug Metabolism (ed. Kalow, W.) 721-727 (Pergamon Press Inc., New York, 1992).
80. Caraco, Y., Sheller, J. & Wood, A.J.J. Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. J. Pharmacol. Exp. Ther. 290, 413-422 (1999).
81. Kirchheiner, J. et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J..
82. Lalovic, B. et al. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin. Pharmacol. Ther. 79, 461-479 (2006).
83. Heiskanen, T., Olkkola, K.T. & Kalso, E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin. Pharmacol. Ther. 64, 603-611 (1998).
84. Otton, S.V. et al. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin. Pharmacol. Ther. 54, 463-472 (1993).
85. Fromm, M.F., Hofmann, U., Griese, E.-U. & Mikus, G. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. Clin. Pharmacol. Ther. 58, 374-382 (1995).
86. Poulsen, L., Arendt-Nielsen, L., Brøsen, K. & Sindrup, S. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin. Pharmacol. Ther. 60, 636-644 (1996).
87. Borlak, J., Hermann, R., Erb, K. & Thum, T. A rapid and simple CYP2D6 genotyping assay - case study with analgetic tramadol. Metabolism 52, 1439-1443 (2003).
88. Fliegert, F., Kurth, B. & Gohler, K. The effects of tramadol on static and dynamic pupillometry in healthy subjects - the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status. Eur. J. Pharmacol. 61, 257-266 (2005).
89. Slanar, O. et al. Miotic action of tramadol is determined by CYP2D6 genotype. Physiol. Res. E-pub 23 Feb (2006).
90. Slanar, O. et al. CYP2D6 polymorphism, tramadol pharmacokinetics and pupillary response. Eur. J. Clin. Pharmacol. 62, 75-76 (2006).
91. Pedersen, R.S., Damkier, P. & Broøsen, K. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. Clin. Pharmacol. Ther. 77, 458-467 (2005).
92. Levo, A. et al. Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood. Forensic Sci. Int. 135, 9-15 (2003).
93. Laugesen, S. et al. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin. Pharmacol. Ther. 77, 312-323 (2005).
94. Eap, C.B. et al. Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J. Clin. Psychopharmacol. 21, 229-234 (2001).
95. Coller, J.K. et al. Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone. Int. J. Clin. Pharmacol. Ther. (in press, 2007).
96. Crettol, S. et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin. Pharmacol. Ther. 78, 593-604 (2005).
97. Eap, C.B., Bertschy, G., Powell, K. & Baumann, P. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. J. Clin. Psychopharmacol. 17, 113-117 (1997).
98. Begre, S. et al. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J. Clin. Psychopharmacol. 22, 211-215 (2002).
99. Sindrup, S.H. et al. The effect of quinidine on the analgesic effect of codeine. Eur. J. Clin. Pharmacol. 42, 587-591 (1992).
100. Siegle, I. et al. Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 11, 237-245 (2001).
101. Desmeules, J., Gascon, M.-P., Dayer, P. & Magistris, M. Impact of environmental and genetic factors on codeine analgesia. Eur. J. Clin. Pharmacol. 41, 23-26 (1991).
102. Enggaard, T.P. et al. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth. Analg. 102, 146-150 (2006).
103. Poulsen, L. et al. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur. J. Clin. Pharmacol. 51, 289-295 (1996).
104. Eckhardt, K. et al. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 76, 27-33 (1998).
105. Webb, J.A. et al. Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modeling analysis. Br. J. Clin. Pharmacol. 52, 35-43 (2001).
106. Schmidt, H. et al. Affinities of dihydrocodeine and its metabolites to opioid receptors. Pharmacol. Toxicol. 91, 57-63 (2002).
107. Persson, K. et al. Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan. Br. J. Clin. Pharmacol. 39, 182-186 (1995).
108. Poulsen, L. et al. Codeine in post-operative pain: study of the influence of sparteine phenotype and serum concentrations of morphine and morphine-6-glucuronide. Eur. J. Clin. Pharmacol. 54, 451-454 (1998).
109. Maddocks, I. et al. Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J. Pain Symptom Manage. 12, 182-189 (1996).
110. Stamer, U.M. et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 105, 231-238 (2003).
111. Holthe, M. et al. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur. J. Clin. Pharmacol. 58, 353-356 (2002).
112. Holthe, M. et al. Sequence variations in the UDP- glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J. 3, 17-26 (2003).
113. Sawyer, M.B. et al. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin. Pharmacol. Ther. 73, 566-574 (2003).
114. Caraco, Y., Sheller, J. & Wood, A.J. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. J. Pharmacol. Exp. Ther. 278, 1165-1174 (1996).
115. Mikus, G. et al. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. Clin. Pharmacol. Ther. 61, 459-466 (1997).
116. Hasselstrom, J., Yue, Q.Y. & Säwe, J. The effect of codeine on gastrointestinal transit in extensive and poor metabolisers of debrisoquine. Eur. J. Clin. Pharmacol. 53, 145-148 (1997).
117. Susce, M.T., Murray-Carmichael, E. & de Leon, J. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog. Neuro-Psychopharmacol. Biol. Psych. 30, 1356-1358 (2006).
118. Dalén, P., Frengell, C., Dahl, M.-L. & Sjöqvist, F. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther. Drug Monit. 19, 543-544 (1997).
119. Gasche, Y. et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N. Engl. J. Med. 351, 2827-2831 (2004).
120. Koren, G. et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 368, 704 (2006).
121. de Leon, J., Dinsmore, L. & Wedlund, P. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. J. Clin. Psychopharmacol. 23, 420-421 (2003).
122. Dietrich, C.G., Geier, A. & Oude Elferink, R.P. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 52, 1788-1795 (2003).
123. Chan, L.M.S., Lowes, S. & Hirst, B.H. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci. 21, 25-51 (2004).
124. Shitara, Y., Horie, T. & Sugiyama, Y. Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci. 27, 425-446 (2006).
125. Takano, M., Yumoto, R. & Murakami, T. Expression and function of efflux drug transporters in the intestine. Pharmacol. Ther. 109, 137-161 (2006).
126. Fromm, M.F. Importance of P-glycoprotein and blood-tissue barriers. Trends Pharmacol. Sci. 25, 423-429 (2004).
127. Lin, J.H. & Yamazaki, M. Clinical relevance of P-glycoprotein in drug therapy. Drug Metab. Rev. 35, 417-454 (2003).
128. Lin, J.H. & Yamazaki, M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. 42, 59-98 (2003).
129. Wandel, C., Kim, R., Wood, M. & Wood, A. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 96, 913-920 (2002).
130. Rodriguez, M. et al. Effect of P-glycoprotein inhibition on methadone analgesia and brain distribution in the rat. J. Pharm. Pharmacol. 56, 367-374 (2004).
131. Dagenais, C., Graff, C.L. & Pollack, G.M. Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem. Pharmacol. 67, 269-276 (2004).
132. Sadeque, A.J.M. et al. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin. Pharmacol. Ther. 68, 231-237 (2000).
133. Kharasch, E.D., Hoffer, C., Whittington, D. & Sheffels, P. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin. Pharmacol. Ther. 74, 543-554 (2003).
134. Drewe, J. et al. Effect of p-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. Br. J. Clin. Pharmacol. 50, 237-246 (2000).
135. Skarke, C. et al. Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine. Clin. Pharmacol. Ther. 74, 303-311 (2003).
136. Kharasch, E.D., Hoffer, C., Altuntas, T.G. & Whittington, D. Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. J. Clin. Pharmacol. 44, 224-233 (2004).
137. Kharasch, E.D., Hoffer, C. & Whittington, D. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. Br. J. Clin. Pharmacol. 57, 600-610 (2004).
138. Ganapathy, V. & Miyauchi, S. Transport systems for opioid peptides in mammalian tissues. AAPS J. 7, E852-E856 (2005).
139. King, M. et al. Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs. Nat. Neurosci. 4, 268-274 (2001).
140. Chen, C. & Pollack, G.M. Altered disposition and antinociception of [D-penicillamine(2,5)] enkephalin in mdr1a-gene-deficient mice. J. Pharmacol. Exp. Ther. 287, 545-552 (1998).
141. Chen, C. & Pollack, G.M. Enhanced antinociception of the model opioid peptide [D-penicillamine] enkephalin by P-glycoprotein modulation. Pharm. Res. 16, 296-301 (1999).
142. Oude Elferink, R.P. & Zadina, J. MDR1 P-glycoprotein transports endogenous opioid peptides. Peptides 22, 2015-2020 (2001).
143. Owen, A. et al. Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. Br. J. Clin. Pharmacol. 59, 365-370 (2005).
144. Meier, Y. et al. Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology 44, 62-74 (2006).
145. Thorn, M. et al. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br. J. Clin. Pharmacol. 60, 54-60 (2005).
146. Kerb, R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 234, 4-33 (2006).
147. Cascorbi, I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther. 112, 457-473 (2006).
148. Ameyaw, M.-M. et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 11, 217-221 (2001).
149. Siegsmund, M. et al. Association of the P-glycoprotein transporter MDR1 (C3435T) polymorphism with the susceptibility to renal epithelial tumors. J. Am. Soc. Nephrol. 13, 1847-1854 (2002).
150. + natural killer cells. Pharmacogenetics 11, 293-298 (2001).
151. Song, P. et al. G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression. J. Clin. Pharmacol. 46, 373-379 (2006).
152. Hitzl, M. et al. Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics 14, 309-318 (2004).
153. Hoffmeyer, S. et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlations of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97, 3473-3478 (2000).
154. Oselin, K. et al. MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundam. Clin. Pharmacol. 17, 463-469 (2003).
155. Oselin, K. et al. Quantitative determination of MDR1 mRNA expression in peripheral blood lymphocytes: a possible role of genetic polymorphisms in the MDR1 gene. Eur. J. Clin. Invest. 33, 261-267 (2003).
156. Siegmund, W. et al. The effects of the human MDR1 genotype on the expression of duodenal p-glycoprotein and disposition of the probe drug talinolol. Clin. Pharmacol. Ther. 72, 572-583 (2002).
157. Wang, D. et al. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet. Genom. 15, 693-704 (2005).
158. Chowbay, B. et al. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br. J. Clin. Pharmacol. 60, 159-171 (2005).
159. Skarke, C. et al. Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 13, 651-660 (2003).
160. Pauli-Magnus, C. et al. No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. Clin. Pharmacol. Ther. 74, 487-498 (2003).
161. Melichar, J.K., Myles, J.S., Eap, C.B. & Nutt, D.J. Using saccadic eye movements as objective measures of tolerance in methadone dependent individuals during the hydromorphone challenge test. Addict Biol 8, 59-66 (2003).
162. Meineke, I. et al. Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. Br. J. Clin. Pharmacol. 54, 592-603 (2002).
163. Kroetz, D.L. et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13, 481-494 (2003).
164. Kim, R.B. MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. Pharmacogenetics 12, 425-427 (2002).
165. Johne, A. et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther. 72, 584-594 (2002).
166. Coller, J.K. et al. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin. Pharmacol. Ther. 80, 682-690 (2006).
167. Kim, R.B. et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70, 189-199 (2001).
168. Schaeffeler, E. et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 358, 383-384 (2001).
169. Aquilante, C.L., Letrent, S.P., Pollack, G.M. & Brouwer, K.L. Increased brain P-glycoprotein in morphine tolerant rats. Life Sci. 66, PL47-PL51 (2000).
170. Störmer, E., Perloff, M.D., von Moltke, L.L. & Greenblatt, D.J. Methadone inhibits rhodamine123 transport in Caco-2 cells. Drug Metab. Dispos. 29, 954-956 (2001).
171. Matheny, C.J., Lamb, M.W., Brouwer, K.R. & Pollack, G.M. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 21, 778-796 (2001).
172. Deferme, S. & Augustijns, P. The effect of food components on the absorption of P-gp substrates: a review. J. Pharm. Pharmacol. 55, 153-162 (2003).
173. Bourasset, F. & Scherrmann, J.M. Carrier-mediated processes at several rat brain interfaces determine the neuropharmacokinetics of morphine and morphine-6-beta-D-glucuronide. Life Sci 78, 2302-2314 (2006).
174. Borst, P. & Elferink, R.O. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 71, 537-592 (2002).
175. Nies, A.T. et al. Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 129, 349-360 (2004).
176. Scheffer, G.L. et al. Tissue distribution and induction of human multidrug resistant protein 3. Lab. Invest. 82, 193-201 (2002).
177. Hoffmaster, K.A., Zamek-Gliszczynski, M.J., Pollack, G.M. & Brouwer, K.L. Hepatobiliary disposition of the metabolically stable opioid peptide [D-Pen2, D-Pen5]-enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems. J. Pharmacol. Exp. Ther. 311, 1203-1210 (2004).
178. Crowe, A. The influence of P-glycoprotein on morphine transport in Caco-2 cells. Comparison with paclitaxel. Eur. J. Pharmacol. 440, 7-16 (2002).
179. Kastin, A.J., Fasold, M.B. & Zadina, J.E. Endomorphins, Met-enkephalin, Tyr-MIF-1, and the P-glycoprotein efflux system. Drug Metab. Dispos. 30, 231-234 (2002).
180. Konig, J. et al. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta 1461, 377-394 (1999).
181. Saito, S. et al. Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamilyC (ABCC/MRP/CFTR). J. Hum. Genet. 47, 147-171 (2002).
182. Ito, S. et al. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 11, 175-184 (2001).
183. Wang, H. et al. Linkage disequilibrium and haplotype architecture for two ABC transporter genes (ABCC1 and ABCG2) in Chinese population: implications for pharmacogenomic association studies. Ann. Hum. Genet. 68, 563-573 (2004).
184. Lang, T. et al. Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics 14, 155-164 (2004).
185. Kullak-Ublick, G.A. et al. Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology 109, 1274-1282 (1995).
186. Gao, B. et al. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J. Pharmacol. Exp. Ther. 294, 73-79 (2000).
187. Kullak-Ublick, G.A. et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120, 525-533 (2001).
188. Lee, W. et al. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J. Biol. Chem. 280, 9610-9617 (2005).
189. Letschert, K., Keppler, D. & Konig, J. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 14, 441-452 (2004).
190. Lötsch, J. & Geisslinger, G. Current evidence for a genetic modulation of the response to analgesics. Pain 121, 1-5 (2006).
191. Contopoulos-Ioannidis, D.G., Alexiou, G.A., Gouvias, T.C. & Ioannidis, J.P. An empirical evaluation of multifarious outcomes in pharmacogenetics: beta-2 adrenoceptor gene polymorphisms in asthma treatment. Pharmacogenet. Genom. 16, 705-711 (2006).